Big Share Of EU Decentralized Procedures Still Seeking Post-Brexit Home
Executive Summary
Progress is being made with redistributing UK rapporteurships for non-centrally approved medicines, but companies need to keep up the momentum if all procedures are to be reallocated to other EU countries by the Brexit date of March 29, 2019.
You may also be interested in...
Brexit: EU Countries Dragging Feet On At-Risk Medicines
The EU regulatory network is finding it difficult to identify non-centrally authorized medicines that are at risk of Brexit-related shortages, a workshop on medicines availability has heard.
Unease Mounts Over Brexit Drug Shortage Risk
Not enough is known about how industry is preparing for Brexit when it comes to drugs approved via Europe’s mutual recognition and decentralized procedures. National regulators are urging companies to get their house in order.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.